HCRT and obesity due to melanocortin 4 receptor deficiency: Collectively, these findings (summarized in Table 3) suggest that orexins and their receptors might be considered a promising therapeutic target for the treatment of eating disorders and energy metabolism disturbances including obesity, diabetes, and cardiovascular diseases.